Massachusetts–based startup TransMolecular announced in recent weeks that it had completed a phase 1 trial of its radiolabeled synthetic analog of the scorpion venom peptide chlorotoxin (131 I ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback